IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis Approximately 80% of target participants have completed trial participation, strengthening momentum toward database lock and topline analysis https://www.accessnewswire.com/news...ma-trial-advances-toward-completion-a-1172698
IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis Company Continuing Limited Over-Enrollment Activities to Account for Attrition and Support Robust Modified Intent-to-Treat, End-of-Treatment and Exploratory Analyses https://www.accessnewswire.com/news...ent-enrollment-target-in-phase-2-calm-1175965
